SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

ARGX

argenx SE
NEUTRAL
Impact 5/10
Horizonweeks Processed7d 20h ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

The deal adds a complementary peptide platform but is modest relative to argenx's $55.8B market cap. Watch for integration updates and any pipeline milestones that could trigger the contingent payments.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$962.27
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.18%
T+5 · $950.95
Vs SPY
+0.52%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $962.27entry
  2. T+1 · 7d ago +0.96%α +1.33% · $971.55
  3. T+5 · 15h ago −1.18%α +0.52% · $950.95
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

argenx announces acquisition of Unnatural Products (UNP) for up to $1.15 billion, adding a macrocyclic peptide discovery platform. The deal includes $550M upfront cash and up to $595M in milestone payments, expected to close by year-end.

Key Financial Metrics

Deal Value
$1.1B

Key Facts

  • Upfront payment of $550 million in cash on hand
  • Up to $595 million in development and regulatory milestone payments
  • Total potential consideration up to approximately $1.15 billion
  • UNP to continue operating from Santa Cruz, California with current team
  • Acquisition expected to close by end of 2026
  • argenx already held a minority stake in UNP prior to the deal
  • Boards of both companies have approved the transaction

Financial Impact

$550M upfront cash plus up to $595M in milestones, total up to $1.15B

cashdilution (none; cash deal)

Risk Factors

  • Milestone payments may not be achieved if development or regulatory hurdles arise
  • Integration risks despite prior collaboration
  • Customary closing conditions could delay or prevent close

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398049

Track record

23 reports on ARGX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026